Document is current
Any future updates will be listed below
-
Authors
Mishra, Vasudha
Singh, Alka
Korzinkin, Michael
Cheng, Xiangying
Wing, Claudia
Sarkisova, Viktoria
Koppayi, Ashwin L.
Pogorelskaya, Alexandra
Glushchenko, Oksana
Sundaresan, Manu
Thodima, Venkat
Carter, Jack
Ito, Koichi
Scherle, Peggy
Trzcinska, Anna
Ozerov, Ivan
Vokes, Everett E.
Cole, Grayson
Pun, Frank W.
Shen, Le
Miao, Yuxuan
Pearson, Alexander T.
Lingen, Mark W.
Ruggeri, Bruce
Rosenberg, Ari J.
Zhavoronkov, Alex
Agrawal, Nishant
Izumchenko, Evgeny
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01DE027809, R01DE027809, R01DE027809, R01DE027809, R01DE027809, R01DE027809, R01DE027809)
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 30 December 2024
First Online: 11 January 2025
Declarations
:
: All human samples used in this study were obtained by the Human Tissue Resource Center at the University of Chicago following informed written consent, under the Institutional Review Boards (IRB)-approved protocols.
: Not applicable.
: VT, KI, PS, and BR are affiliated with Prelude Therapeutics, a clinical-stage biopharmaceutical company designing and developing novel small molecule therapies that target the key drivers of cancer cell growth and resistance. MK, VS, AO, OG, IO, FP, and AZ are affiliated with InSilico Medicine, a company developing an AI-based end-to-end integrated pipeline for drug discovery and development. The remaining authors declare no conflict of interest.
